SCHEMBL980892

SCHEMBL980892

CCc1ccccc1-c1ccccc1O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GABRA1 P14867 1/20 0.50
GABRB2 P47870 1/20 0.50
HSPA5 P11021 1/20 0.46
ANPEP P15144 1/20 0.46
DPP4 P27487 1/20 0.46
AKR1B1 P15121 1/20 0.45
ALDH1A1 P00352 1/20 0.44
HPGD P15428 1/20 0.44
BCL2L1 Q07817 1/20 0.44
HSD17B10 Q99714 1/20 0.44
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
CSNK2A3 Q8NEV1 1/20 0.43
TSHR P16473 3/20 0.42
CYP2D6 P10635 2/20 0.41
HIF1A Q16665 1/20 0.41
HTR1A P08908 1/20 0.41
TAAR1 Q96RJ0 1/20 0.40
LMNA P02545 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29362539 1.00 GABRA1 (0.50) GABRA1GABRB2HSPA5ANPEPDPP4
SCHEMBL323999 0.98 GABRA1 (0.48) GABRA1GABRB2HSPA5ANPEPDPP4
Ammonia Solution, Strong SCHEMBL324961 0.98 GABRA1 (0.48) GABRA1GABRB2HSPA5ANPEPDPP4
SCHEMBL198461 0.85 CSNK2A2 (0.52) GABRA1GABRB2DPP4ALDH1A1CSNK2A2
SCHEMBL5587931 0.85 GABRA1 (0.56) GABRA1GABRB2HSPA5ANPEPDPP4
SCHEMBL10679098 0.84 GABRA1 (0.48) GABRA1GABRB2HSPA5ANPEPDPP4
SCHEMBL9638702 0.84 ANPEP (0.49) GABRA1GABRB2HSPA5ANPEPDPP4
SCHEMBL983104 0.84 GABRA1 (0.48) GABRA1GABRB2HSPA5ANPEPDPP4
SCHEMBL10011887 0.84 HSP90AA1 (0.50) GABRA1GABRB2ANPEPDPP4ALDH1A1
SCHEMBL11382359 0.83 CSNK2A2 (0.50) GABRA1GABRB2DPP4ALDH1A1CSNK2A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 56 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113122241-A Quantum dot material and preparation method thereof, quantum dot light-emitting diode and light-emitting device TCL集团股份有限公司 2021-07-16 CN claimed
EP-0596129-A1 PHASE DIFFERENCE COMPENSATION FILM IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1994-05-11 EP claimed
EP-4446310-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND Asahi Kasei Kabushiki Kaisha (JP) 2024-10-16 EP disclosed
US-20230339994-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE FUSHIMI PHARMACEUTICAL CO., LTD. (JP) 2023-10-26 US disclosed
EP-4202013-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE Fushimi Pharmaceutical Co., Ltd. (JP) 2023-06-28 EP disclosed
WO-2023106377-A1 METHOD FOR PRODUCING BLOCKED ISOCYANATE COMPOUND AND METHOD FOR PRODUCING ISOCYANATE COMPOUND 旭化成株式会社 2023-06-15 WO disclosed
EP-2275405-B1 PROCESS FOR PRODUCING ISOCYANATE USING DIARYL CARBONATE ASAHI CHEMICAL IND (JP) 2019-04-24 EP disclosed
EP-2275406-B1 PROCESS FOR PRODUCING ISOCYANATE ASAHI CHEMICAL IND (JP) 2018-11-28 EP disclosed
CN-105246940-B Optical semiconductor sealing solidification compound 株式会社大赛璐 2018-09-04 CN disclosed
CN-108430970-A Bisphenol compound and aromatic copolycarbonate 本州化学工业株式会社 2018-08-21 CN disclosed
EP-2792673-B1 Carbamic acid ester derivatives for the production of isocyanate and aromatic hydroxy compounds ASAHI CHEMICAL IND (JP) 2018-07-25 EP disclosed
CN-101186577-A Liquid crystal monomer with reaction character and preparation method thereof NORTHWEST IND UNIVERSITY (CN) 2008-05-28 CN disclosed
CN-101007798-A Benzodioxole derivatives and their preparation method and medicinal uses POISON MED INST PLA MED ACAD (CN) 2007-08-01 CN disclosed
US-6391925-B1 MICROBIOCIDES; ANTISEPTICS ECOLAB INC. 2002-05-21 US disclosed
EP-0778821-B1 ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF ZENECA LTD (GB) 1999-10-20 EP disclosed
US-5965741-A ANTIINFLAMMATORY, ANTIPYRETIC AND ANTIDIARRHOEAL PROPERTIES ZENECA LIMITED (GB) 1999-10-12 US disclosed
EP-0786699-A1 Positive photoresist composition Fuji Photo Film Co., Ltd. (JP) 1997-07-30 EP disclosed
EP-0778821-A1 ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF ZENECA LIMITED (GB) 1997-06-18 EP disclosed
WO-1996006822-A1 ORTHO-SUBSTITUTED AROMATIC ETHER COMPOUNDS AND THEIR USE IN PHARMACEUTICAL COMPOSITIONS FOR PAIN RELIEF ZENECA LIMITED (GB) 1996-03-07 WO disclosed
EP-0596129-A1 PHASE DIFFERENCE COMPENSATION FILM IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1994-05-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230339994-A1 CYCLIC PHOSPHAZENE COMPOUND HAVING OXAPHOSPHORIN RING-CONTAINING STRUCTURE PFAS, PHOSPHO1, PAF1 GABRA1 2733/4885GABRB2 2758/4885HSPA5 4078/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.